Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/47493
Title: Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis
Authors: Maneechotesuwan K.
Singh D.
Fritscher L.G.
Dursunoğlu, N.
Abhijith P.G.
Phansalkar A.
Aggarwal B.
Pizzichini, Emilio
Chorazy, Justyna
Burnett, Heather
Keywords: Asthma quality of life questionnaire
ICS/LABA
Network meta-analysis
Systematic review
fluticasone propionate plus salmeterol
bronchodilating agent
corticosteroid
fluticasone
fluticasone propionate plus salmeterol
formoterol fumarate
adolescent
adult
asthma
Asthma Control Questionnaire
Asthma Quality of Life Questionnaire
child
female
follow up
forced expiratory volume
human
lung function
male
meta analysis
monotherapy
multicenter study (topic)
network meta-analysis
quality of life
randomized controlled trial (topic)
Review
severe asthma
systematic review
asthma
Bayes theorem
drug combination
inhalational drug administration
Administration, Inhalation
Adrenal Cortex Hormones
Asthma
Bayes Theorem
Bronchodilator Agents
Drug Combinations
Fluticasone
Fluticasone-Salmeterol Drug Combination
Formoterol Fumarate
Humans
Network Meta-Analysis
Quality of Life
Publisher: W.B. Saunders Ltd
Abstract: Objective: This network meta-analysis (NMA) compared fixed-dose, twice daily fluticasone propionate/salmeterol (FP/Sal) vs. inhaled corticosteroid (ICS) and other ICS/long-acting beta-agonists (LABA) treatments, including when administered using maintenance and reliever therapy (MART) regimens, in terms of improvements in health-related quality of life (HRQoL). The relationship between changes in asthma control and HRQoL was assessed. Methods: Articles published between 2001 and 2021, reporting change from baseline (CFB) in Asthma Quality of Life Questionnaire (AQLQ) in patients with moderate-to-severe asthma, were identified by a systematic review. Random effects Bayesian NMAs derived estimates of the mean difference in CFB in AQLQ vs. other interventions connected to the network (included 15 studies). Sensitivity analyses explored the impacts of differences in follow-up duration, baseline asthma control, the inclusion of observational studies, adjusting for baseline FEV1, and low-medium ICS dose arms only. Linear regression analysis compared CFBs in AQLQ and Asthma Control Questionnaire (ACQ) score. Results: Mean CFB in AQLQ with FP/Sal vs. comparators demonstrated expected ranked effects: mean difference 0.65 [95% credible interval: 0.54, 0.78] versus placebo, 0.58 [ 0.33, 0.84] versus LABA, 0.21 [ 0.13, 0.31] versus ICS alone, 0.06 [?0.04, 0.19] versus other ICS/LABA, and 0.00 [?0.13, 0.14] versus ICS/formoterol MART. Sensitivity analyses largely showed consistent results. Improvements in AQLQ and ACQ were strongly correlated (R = 0.94). Conclusions: This NMA demonstrates that HRQoL is responsive to treatment, is strongly related to asthma control and that it can be well-managed in patients with moderate-to-severe asthma using regular treatment with inhaled FP/Sal. © 2022 The Authors
URI: https://doi.org/10.1016/j.rmed.2022.106993
https://hdl.handle.net/11499/47493
ISSN: 0954-6111
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

4
checked on Oct 13, 2024

WEB OF SCIENCETM
Citations

3
checked on Oct 31, 2024

Page view(s)

66
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.